Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Sponsor: Bio Products Laboratory
Terminated
Study no longer required as Optivate German license expired in Sep-2017.
Other terminated trials from Bio Products Laboratory
Other Haemophilia A trials with similar outcome
A PHASE4 clinical study on Haemophilia A, this trial is terminated or withdrawn. The trial is conducted by Bio Products Laboratory and has accumulated 13 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE4
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE4
-
Feb 2018 — May 2018 [monthly]
Terminated PHASE4
-
Aug 2017 — Feb 2018 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bio Products Laboratory
For direct contact, visit the study record on ClinicalTrials.gov .